Chemoradiotherapy is a treatment that combines chemotherapy with radiation therapy. Also called chemoradiation.
Researchers at Trinity College Dublin have identified, for the first time in esophageal cancer, the cancer killing capability of a lesser-known type of immune cell, presenting a new potential therapeutic target.
A new special edition of the International Journal of Radiation Oncology* Biology* Physics focuses on the roles of imaging in radiation oncology. The collection explores topics such as improving accuracy with patient positioning, defining radiation therapy volumes using imaging, imaging of functional biomarkers, the role of imaging in post-treatment care, machine learning and artificial intelligence.
The European Society of Coloproctology has undertaken a major international audit of colorectal operations to understand which are most widely used techniques across the world, which appear to be associated with the best outcomes and where further research needs to be undertaken.
Non-small cell lung cancer patients survive longer when their treatment includes durvalumab following platinum-based chemoradiotherapy, according to research led by Moffitt Cancer Center.
About 50,000 people in the U.S. are diagnosed annually with head, neck, nasal and oral cancers. Most are treated with radiation, and of those, 70-80 percent develop a painful and debilitating side effect called severe oral mucositis.
Atlantic Health System is now enrolling patients in four pancreatic cancer clinical trials. Angela Alistar, MD, a nationally known expert on pancreatic cancer, is serving as national Principal Investigator on the first trial and as local PI on three other trials.
A coveted British Medical Journal award was recently bestowed on the Papillon Contact X-ray Brachytherapy team at the Clatterbridge Cancer Centre. The Cancer Care Team of the year category was won by the entry—Papillon for Rectal Cancer.
It’s unclear whether all patients with advanced rectal cancer need chemoradiotherapy, or whether some can forego the treatment and therefore be spared its side effects.
Analysis of a clinical trial, RTOG Foundation 3504, finds that nivolumab immunotherapy can be administered safely in conjunction with radiation therapy and chemotherapy for patients with newly diagnosed local-regionally advanced head and neck cancers.
A new study has identified a way to turn a humble cocktail of bacteria and vegetables into a targeted system that finds and kills colorectal cancer cells.
A blood test for the human papillomavirus, or HPV, may help researchers forecast whether patients with throat cancer linked to the sexually transmitted virus will respond to treatment, according to preliminary findings from the University of North Carolina Lineberger Comprehensive Cancer Center.
Female patients with locally advanced esophageal cancer that is treated with chemotherapy and radiation therapy before surgery are more likely to have a favorable response to the treatment than male patients are, and women are less likely to experience cancer recurrence, according to a study published online today in The Annals of Thoracic Surgery.
A late breaking subanalysis of the phase III CONVERT trial presented at the European Lung Cancer Conference shows that white blood cell boosting drugs are safe during concurrent chemo-radiotherapy of small cell lung cancer (SCLC).
Elderly patients with early-stage esophageal cancer that received treatment had an increased 5-year overall survival when compared to patients who received observation with no treatment.
The American Society for Radiation Oncology today issued a new clinical guideline for the management of oropharyngeal cancer.
Post-operative treatment intensification with chemoradiotherapy does not achieve better outcomes when compared to post-operative chemotherapy in patients with gastric cancer who have already undergone pre-operative chemotherapy, according to phase III data presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain.
Patients with high-risk, locally advanced rectal cancer could benefit from neoadjuvant chemotherapy before undergoing chemoradiotherapy, suggest the results of a pooled analysis.
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer.
Head and neck cancer patients may no longer have to undergo invasive post-treatment surgery to remove remaining cancer cells, as research shows that innovative scanning-led surveillance can help identify the need for, and guidance of, neck dissection.
Patients who received chemotherapy after surgical resection of pancreatic cancer have fewer distant disease recurrences and longer overall survival than those who also had adjuvant chemoradiation therapy.